A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

Clinical trial NCT00315731 · COMPLETED

Trial details

NCT number: NCT00315731
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, Follicular

Start date: 2003-03-31
Primary completion: 2006-12-04
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.